The addition of adjuvant nivolumab to standard-of-care radiotherapy and cisplatin improved survival for patients with locally ...

In the primary efficacy population, the median progression-free survival was not reached in the nivolumab-ipilimumab arm and was 5.9 months in the chemotherapy arm. The combination of nivolumab and ...

Oncology nurses can educate patients on the benefits of subcutaneous administration, including reduced time in the infusion ...

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Subcutaneous Opdivo improves cancer care by offering faster, accessible therapy, reducing time toxicity and expanding patient ...

Post-operative nivolumab significantly improved disease-free survival in resected locally advanced head and neck cancer, ...

Shares of I-Mab (NASDAQ:IMAB) jumped 15% in midday trading Monday after the biotech company said it plans to focus on ...

On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid ...

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Paranasal Sinus And Nasal Cavity Cancer.

The approval of Opdivo Qvantig was supported by data from the randomized, open-label phase 3 CheckMate-67T study.

Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for ...